What is Mesoblast Limited (MSBau)?
Mesoblast Limited is an Australian biotechnology company specializing in the development of cellular medicines based on mesenchymal lineage adult stem cells. The company focuses on regenerative medicine applications, targeting inflammatory diseases, cardiovascular conditions, and orthopedic disorders. Mesoblast conducts research and clinical development to advance its proprietary cell therapy platforms, aiming to provide treatments that modulate immune responses and promote tissue repair. It collaborates with academic institutions, healthcare providers, and industry partners to support its product pipeline and regulatory approvals. The company operates within the biopharmaceutical sector, emphasizing innovation in cell-based therapies for unmet medical needs.
Mesoblast Limited Stock Price Today: Live Overview
The price today is shaped by real-time market activity with Soleno Therapeutics Inc priced at A$2.21. The intraday movement spans from A$2.06 to A$2.18, with a daily change percentage of +5.8252%.
FAQ: Mesoblast Limited (MSBau)
What is the current price of MSBau stock?
The current price stands at A$2.21.
Does MSBau pay dividends?
Mesoblast Limited does not currently pay dividends.
Does MSBau have a formal corporate presence or regional headquarters in the UAE?
Mesoblast Limited operates in the UAE through partners and does not have an official office or subsidiary.
What is MSBau best known for?
Mesoblast Limited is most famous for its development of regenerative medicine and cellular therapies.
What assets are typically shown together with MSBau?
Commonly shown alongside MSBau: Optimum Communications Inc, Firefly Aerospace Inc., SPDR S&P 400 U.S. Mid Cap UCITS ETF
Latest shares articles



